A series of novel neuroprotective blood brain barrier penetrating flavonoid drugs to treat acute ischemic stroke

Current Pharmaceutical Design

Volumn 18, Issue 25, 2012, Pages 3694-3703

  Lapchak, Paul A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Chalcone; Clinical function; Flavone; Flavonoid; MDCK; Pleiotropic; RSCEM; Screening

Indexed keywords

3,3',4' TRIHYDROXY ALPHA NAPHTHOFLAVONE; 4',5' DIMETHYL 2',3,4 TRIDYDROXYCHALCONE; 6 PROPYL 3,3',4' TRIHYDROXYFLAVONE; ALPHA NAPHTHOFLAVONE; BAICALEIN; FISETIN; FLAVONE DERIVATIVE; FLAVONOID; NEUROPROTECTIVE AGENT; POLYPHENOL DERIVATIVE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CELL SURVIVAL; DRUG EFFICACY; DRUG RELEASE; DRUG SYNTHESIS; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; LIPOPHILICITY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; FLAVONOIDS; HUMANS; NEUROPROTECTIVE AGENTS; STROKE;

EID: 84867513388     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802002652     Document Type: Article

References (85)

1. Maher P, Salgado KF, Zivin JA, Lapchak PA. A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res 2007; 1173: 117-25.
2. Bernas T, Dobrucki J. Mitochondrial and nonmitochondrial reduction of MTT: interaction of MTT with TMRE, JC-1, and NAO mitochondrial fluorescent probes. Cytometry 2002; 47(4): 236-42.
3. Berridge MV, Tan AS. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 1993; 303(2): 474-82.
4. Lapchak PA, Maher P, Schubert D, Zivin JA. Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience 2007; 150(3): 585-91.
5. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart Disease and Stroke Statistics-2012 Update. Circulation 2011 December 15, 2011; DOI: 10.1161/CIR.0b013e31823ac046.
6. NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333(24): 1581-7.
7. Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs 2002; 11(11): 1623-32.
8. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359(13):1317-29.
9. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 2009; 40(7): 2438-41.
10. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010 May 15; 375(9727): 1695-703.
11. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 2004 Sep; 24(9): 945-63.
12. Moskowitz MA, Lo EH, Ladecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010; 67(2): 181-98.
13. Liebeskind DS, Kasner SE. Neuroprotection for ischaemic stroke: an unattainable goal? CNS Drugs 2001; 15(3): 165-74.
14. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22(9): 391-7.
15. Siesjo BK, Katsura K, Zhao Q, et al. Mechanisms of secondary brain damage in global and focal ischemia: a speculative synthesis. J Neurotrauma 1995; 12(5): 943-56.
16. Siesjo BK, Siesjo P. Mechanisms of secondary brain injury. Eur J Anaesthesiol 1996; 13(3): 247-68.
17. Lapchak PA, Araujo DM. Advances in hemorrhagic stroke therapy: conventional and novel approaches. Expert Opin Emerg Drugs 2007; 12(3): 389-406.
18. Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs 2007; 12(1): 97-112.
19. Petty MA, Wettstein JG. Elements of cerebral microvascular ischaemia. Brain Res Rev 2004; 36: 23-34.
20. Jung HA, Park JC, Chung HY, Kim J, Choi JS. Antioxidant flavonoids and chlorogenic acid from the leaves of Eriobotrya japonica. Arch Pharm Res 1999; 22(2): 213-8.
21. Hirose K, Chan PH. Blockade of glutamate excitotoxicity and its clinical applications. Neurochem Res 1993; 18(4): 479-83.
22. Kucukkaya B, Haklar G, Yalcin AS. NMDA excitotoxicity and free radical generation in rat brain homogenates: application of a chemiluminescence assay. Neurochem Res 1996; 21(12): 1535-8.
23. Mattson MP. Neuroprotective signal transduction: relevance to stroke. Neurosci Biobehav Rev 1997; 21(2): 193-206.
24. Prass K, Dirnagl U. Glutamate antagonists in therapy of stroke. Restor Neurol Neurosci 1998; 13(1-2): 3-10.
25. Lapchak PA, Wu Q. Vascular dysfunction in brain hemorrhage: translational pathways to developing new treatments from old targets. Journal of Neurology and Neurophysiology 2011(S1): doi: 10.4172/2155-9562.S1-e001.
26. Lapchak PA, Zivin JA. The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp Neurol 2009; 215(1): 95-100.
27. Chan PH, Schmidley JW, Fishman RA, Longar SM. Brain injury, edema, and vascular permeability changes induced by oxygen-derived free radicals. Neurology 1984; 34(3): 315-20.
28. Facchinetti F, Dawson VL, Dawson TM. Free radicals as mediators of neuronal injury. Cell Mol Neurobiol 1998; 18(6): 667-82.
29. Love S. Oxidative stress in brain ischemia. Brain Pathol 1999; 9(1): 119-31.
30. White BC, Sullivan JM, DeGracia DJ, et al. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci 2000; 179(S 1-2): 1-33.
31. Dewar DPY, McCulloch J. Drug development for stroke: importance of protecting cerebral white matter. Eur J Pharmacol 1999; 375: 47-50.
32. Fisher M. The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc Dis 2004; 17: 1-6.
33. Michel P, Bogousslavsky J. Penumbra is brain: no excuse not to perfuse. Ann Neurol 2005; 58(5): 661-3.
34. Moustafa RR, Baron JC. Imaging the penumbra in acute stroke. Curr Atheroscler Rep 2006; 8(4): 281-9.
35. Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol 2009 Aug; 157(7): 1157-71.
36. Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009 Mar; 40(3 Suppl): S111-4.
37. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother 2010; 11(10): 1753-63.
38. Lapchak PA. Erythropoietin Molecules to Treat Acute Ischemic Stroke: A Translational Dilemna! Expert Opin Investig Drugs 2010; 19(10): 1179-86.
39. Lapchak PA. Taking A Light Approach to Treating Acute Ischemic Stroke Patients: Transcranial Near-Infrared Laser Therapy Translational Science. Ann Med 2010; 42(8): 576-86.
40. Lapchak PA. Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective. Expert Opin Investig Drugs 2011; 20(1): 13-22.
41. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 2007; 205(1): 20-5.
42. Lapchak PA. Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims. Trans Stroke Res 2011; 2(2): 129-35.
43. Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Trans Stroke Res. [Perspective Review] 2010; 1(2): 96-107.
44. Muir KW. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke 2002; 33(6): 1545-50.
45. Fisher M. New approaches to neuroprotective drug development. Stroke 2011; 42(1 Suppl): S24-7.
46. Goldfinger TM. Beyond the French paradox: the impact of moderate beverage alcohol and wine consumption in the prevention of cardiovascular disease. Cardiol Clin 2003; 21(3): 449-57.
47. Kar P, Laight D, Shaw KM, Cummings MH. Flavonoid-rich grapeseed extracts: a new approach in high cardiovascular risk patients? Int J Clin Pract 2006; 60(11): 1484-92.
48. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001; 74(4): 418-25.
49. Renaud S, Ruf JC. The French paradox: vegetables or wine. Circulation 1994 Dec; 90(6): 3118-9.
50. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004; 79(5): 727-47.
51. Scalbert A, Manach C, Morand C, Remesy C, Jimenez L. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 2005; 45(4): 287-306.
52. Dajas F, Rivera-Megret F, Blasina F, et al. Neuroprotection by flavonoids. Braz J Med Biol Res 2003; 36(12): 1613-20.
53. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5(6): 493-506.
54. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 2006; 545(1): 51-64.
55. Dajas F, Rivera F, Blasina F, et al. Cell culture protection and in vivo neuroprotective capacity of flavonoids. Neurotox Res 2003; 5(6): 425-32.
56. Rivera F, Urbanavicius J, Gervaz E, Morquio A, Dajas F. Some aspects of the in vivo neuroprotective capacity of flavonoids: bioavailability and structure-activity relationship. Neurotox Res 2004; 6(7-8): 543-53.
57. Woodman OL, Chan E. Vascular and anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol Physiol 2004; 31(11): 786-90.
58. Lotito SB, Frei B. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: Cause, consequence, or epiphenomenon? Free Radic Biol Med 2006; 41(12): 1727-46.
59. Ishige K, Schubert D, Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med 2001; 30(4): 433-46.
60. Zhao B. Natural antioxidants for neurodegenerative diseases. Mol Neurobiol 2005; 31(1-3): 283-93.
61. Bei W, Zang L, Guo J, et al. Neuroprotective effects of a standardized flavonoid extract from Diospyros kaki leaves. J Ethnopharmacol. [Research Support, Non-U.S. Gov't] 2009; 126(1): 134-42.
62. Zhang HF, Hu XM, Wang LX, Xu SQ, Zeng FD. Protective effects of scutellarin against cerebral ischemia in rats: evidence for inhibition of the apoptosis-inducing factor pathway. Planta medica 2009; 75(2): 121-6.
63. Xue X, Qu XJ, Yang Y, et al. Baicalin attenuates focal cerebral ischemic reperfusion injury through inhibition of nuclear factor kappaB p65 activation. Biochem Biophys Res Commun. [Research Support, Non-U.S. Gov't] 2010; 403(3-4): 398-404.
64. Yao Y, Han DD, Zhang T, Yang Z. Quercetin improves cognitive deficits in rats with chronic cerebral ischemia and inhibits voltage-dependent sodium channels in hippocampal CA1 pyramidal neurons. Phytother Res. [Research Support, Non-U.S. Gov't] 2010; 24(1): 136-40.
65. Jin G, Arai K, Murata Y, et al. Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia. Stroke 2008; 39(9): 2538-43.
66. Liu C, Wu J, Xu K, et al. Neuroprotection by baicalein in ischemic brain injury involves PTEN/AKT pathway. J Neurochem 2010; 112(6): 1500-12.
67. Lapchak PA. A clinically relevant rabbit embolic stroke model for acute ischemic stroke therapy development: mechanisms & targets. In: Lapchak PA, Zhang JH, Eds.: Translational Stroke Research: From Target Selection to Clinical Trials, Springer, USA; 2011.
68. Hebert P, Gaziano J, Chan K, Hennekens C. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278(4): 313-21.
69. Li Y, Maher P, Schubert D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 1997; 19: 453-63.
70. Lapchak PA, KcKim, J.M. CeeTox™ analysis of CNB-001 a novel curcumin-based neurotrophic/neuroprotective lead compound to treat stroke: comparison with NXY-059 and Radicut. Trans Stroke Res 2011; 2(1): 51-59.
71. Lapchak PA, Schubert D, Maher P. De-risking of Stilbazulenyl nitrone (STAZN), a Lipophilic Nitrone to Treat Stroke Using a Unique Panel of In vitro Assays. Trans Stroke Res 2011; 2(2): 209-17.
72. Silverman R. The Organic Chemistry of Drug Design and Drug Action: Academic Press; 2004.
73. Huang MT, Smart RC, Wong CQ, Conney AH. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1988; 48(21): 5941-6.
74. Liao HL, Hu MK. Synthesis and anticancer activities of 5,6,7-trimethylbaicalein derivatives. Chem Pharm Bull (Tokyo) 2004; 52(10): 1162-5.
75. Harikrishnan LS, Hollis Showalter HD. A novel synthesis of 2,3-disubstituted benzopyran-4-onbes and application to the solid phase. Tetrahedron Lett 2000; 56: 515-19.
76. Vazquez J, Albericia F. A convenient semicarbazide resin for the solid-phase synthesis of peptide ketones and aldehydes. Tetrahedron Lett 2006; 47: 1657-61.
77. Lawrence NJ, Rennison D, McGown AT, et al. Linked parallel synthesis and MTT bioassay screening of substituted chalcones. J Comb Chem 2001; 3(5): 421-6.
78. Lin YM, Zhou Y, Flavin MT, Zhou LM, Nie W, Chen FC. Chalcones and flavonoids as anti-tuberculosis agents. Bioorg Med Chem 2002; 10(8): 2795-802.
79. Razgulin AV, Mecozzi S. Binding properties of aromatic carbon-bound fluorine. J Med Chem 2006; 49(26): 7902-6.
80. Weber J. Current status of virtual combinatorial library design. QSAR Comb Sci 2005; 24(7): 809-23.
81. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. [Review] 2005; 2(4): 541-53.
82. Liu Y, Dargusch R, Maher P, Schubert D. A broadly neuroprotective derivative of curcumin. J Neurochem 2008; 105(4): 1336-45.
83. Tan S, Schubert D, Maher P. Oxytosis: A novel form of programmed cell death. Curr Top Med Chem 2001; 1(6): 497-506.
84. Aly HA, Domenech O. Aroclor 1254 induced cytotoxicity and mitochondrial dysfunction in isolated rat hepatocytes. Toxicology 2009; 262(3): 175-83.
85. Jackson-Friedman C, Lyden PD, Nunez S, Jin A, Zweifler R. High dose baclofen is neuroprotective but also causes intracerebral hemorrhage: a quantal bioassay study using the intraluminal suture occlusion method. Exp Neurol 1997; 147(2): 346-52.